Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tesaglitazar. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 19/20 | 1.00 |
| ▸ | PPARG known ✓ | P37231 | 14/20 | 1.00 |
| ▸ | PPARD | Q03181 | 10/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tesaglitazar SCHEMBL13602606 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL600880 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| SCHEMBL5368994 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL3162078 | 1.00 | PPARA (1.00) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL7211452 | 0.98 | PPARA (0.96) | PPARAPPARGPPARD | |
| Tesaglitazar SCHEMBL7211447 | 0.97 | PPARA (0.94) | PPARAPPARGPPARD | |
| SCHEMBL3262954 | 0.91 | PPARA (0.83) | PPARAPPARGPPARD | |
| SCHEMBL3262951 | 0.91 | PPARA (0.83) | PPARAPPARGPPARD | |
| SCHEMBL5993854 | 0.90 | PPARA (0.82) | PPARAPPARGPPARD | |
| SCHEMBL28649134 | 0.90 | PPARA (0.82) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7903 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137661-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | GENFIT (FR) | 2026-05-21 | — | — | US | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4615433-A1 | PPAR-ALPHA/GAMMA AGONIST FOR USE IN THE TREATMENT OF LIVER FAILURE | Genfit (FR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025137151-A2 | DENDRIMER COMPOSITIONS FOR THE TREATMENT OF ATHEROSCLEROSIS, OBESITY, AND METABOLIC SYNDROMES | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| US-20250082781-A1 | METHODS OF LOWERING BLOOD GLUCOSE AND TREATING TYPE 2 DIABETES BY ACTIVATION OF PDE4D3 | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2025-03-13 | — | — | US | claimed |
| EP-1237854-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3- 4-(2- 4-METHANESULFONYLOXYPHENYL ETHOXY) PHENYL] PROPANOIC ACID | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | claimed |
| WO-2002050051-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002013812-A1 | METHODS FOR TREATING INFLAMMATORY DISEASES | PERSHADSINGH HARRIHAR A (US) | 2002-02-21 | — | — | WO | claimed |
| EP-1150678-A1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | claimed |
| US-6258850-B1 | SULFONATE DERIVATIVES OF ETHER, ACIDS AS DRUGS | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | claimed |
| WO-2001040171-A1 | CRYSTALLINE FORM OF (S)-2 ETHOXY-3-[4-(2-{4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| WO-2001040169-A1 | COMMINUTED FORM OF (S)-2-ETHOXY -3-[4-(2- {4-METHANESULFONYLOXYPHENYL} ETHOXY) PHENYL] PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | claimed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | claimed |
| WO-2000045818-A1 | USE OF 3-HYDROXY-3-METHYLGLUTARYL COENZYM A REDUCTASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF DIABETIC NEUROPATHY | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | claimed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | claimed |